What is TELA's current stock price?

TELA (TELA Bio, Inc.) is currently trading at $0.89 with a market cap of $39.8M.

What sector is TELA Bio, Inc. in?

TELA Bio, Inc. (TELA) operates in the Healthcare sector, specifically in the Medical - Devices industry.

Is TELA a good stock to buy?

Analysts have a Buy consensus on TELA with a price target of $3.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TELA TELA Bio, Inc.

Healthcare

$0.89-3.51%ClosedMarket Cap: $39.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-9.80

P/S

0.49

EV/EBITDA

-1.71

DCF Value

$1.17

FCF Yield

-75.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

67.3%

Operating Margin

-41.8%

Net Margin

-49.3%

ROE

-1344.5%

ROA

-57.0%

ROIC

-64.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$19.1M	$-12.3M	$—
Q4 null	$20.9M	$-9.0M	$—
FY null	$80.3M	$-38.8M	$—
Q3 null	$20.7M	$-8.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$3.00

Target (Median)

$3.00

Target Range

$3.00 - $3.00

1 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell

CitizensMarket Outperform

2026-03-27

Canaccord GenuityBuy

2026-03-25

Piper SandlerNeutral

2026-03-25

Lake StreetBuy

2026-03-25

Lake StreetBuy

2025-12-01

Trading Activity

Insider Trades

View All

Langstein Howard N.officer: Chief Medical Officer

SellWed Mar 11

Langstein Howard N.officer: Chief Medical Officer

SellWed Mar 11

KOBLISH ANTONYdirector, officer: Chief Executive Officer

SellTue Feb 24

KOBLISH ANTONYdirector, officer: Chief Executive Officer

SellTue Feb 24

KOBLISH ANTONYdirector, officer: Chief Executive Officer

SellTue Feb 24

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

1.30

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Peers

COEP

CTSO

CUE